Apogee Therapeutics (NASDAQ:APGE) Shares Up 3.3%

Apogee Therapeutics, Inc. (NASDAQ:APGE)’s share price traded up 3.3% on Wednesday . The company traded as high as $52.53 and last traded at $52.34. 12,165 shares changed hands during trading, a decline of 98% from the average session volume of 635,828 shares. The stock had previously closed at $50.66.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the stock. Jefferies Financial Group raised their price target on shares of Apogee Therapeutics from $37.00 to $75.00 and gave the company a “buy” rating in a report on Wednesday, March 6th. Stifel Nicolaus raised their price target on shares of Apogee Therapeutics from $46.00 to $95.00 and gave the company a “buy” rating in a report on Tuesday, March 5th. Wedbush reiterated an “outperform” rating and issued a $87.00 target price (up previously from $40.00) on shares of Apogee Therapeutics in a report on Tuesday, March 5th. Finally, Guggenheim lifted their target price on shares of Apogee Therapeutics from $44.00 to $91.00 and gave the stock a “buy” rating in a report on Tuesday, March 5th. Seven analysts have rated the stock with a buy rating, According to MarketBeat.com, Apogee Therapeutics has an average rating of “Buy” and an average price target of $71.83.

Apogee Therapeutics Stock Down 6.1 %

The firm’s 50-day simple moving average is $53.04 and its 200-day simple moving average is $34.13.

Apogee Therapeutics (NASDAQ:APGE) last posted its quarterly earnings results on Tuesday, March 5th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.45) by $0.13. Sell-side analysts predict that Apogee Therapeutics, Inc. will post -2.67 earnings per share for the current fiscal year.

Institutional Trading of Apogee Therapeutics

Several institutional investors have recently made changes to their positions in the business. American International Group Inc. boosted its position in shares of Apogee Therapeutics by 4.8% during the 4th quarter. American International Group Inc. now owns 10,203 shares of the company’s stock valued at $285,000 after acquiring an additional 471 shares in the last quarter. SG Americas Securities LLC boosted its position in shares of Apogee Therapeutics by 34.0% during the 4th quarter. SG Americas Securities LLC now owns 6,607 shares of the company’s stock valued at $185,000 after acquiring an additional 1,676 shares in the last quarter. The Manufacturers Life Insurance Company boosted its position in shares of Apogee Therapeutics by 3.5% during the 4th quarter. The Manufacturers Life Insurance Company now owns 51,100 shares of the company’s stock valued at $1,428,000 after acquiring an additional 1,745 shares in the last quarter. Amalgamated Bank acquired a new stake in shares of Apogee Therapeutics during the 3rd quarter valued at about $52,000. Finally, Legal & General Group Plc acquired a new stake in shares of Apogee Therapeutics during the 3rd quarter valued at about $68,000. 79.04% of the stock is currently owned by institutional investors and hedge funds.

About Apogee Therapeutics

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.